You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA781
  • Published:  30 March 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 156 KB)

    Published:
    30 March 2022

Final draft guidance

  • Final draft guidance

  • Public committee slides (PDF 1.19 MB)

    Published:
    03 March 2022
  • Final appraisal document Managed access agreement (PDF 438 KB)

    Published:
    03 March 2022
  • Final appraisal document (PDF 271 KB)

    Published:
    03 March 2022
  • Committee papers (PDF 10.13 MB)

    Published:
    25 April 2022

Invitation to participate

  • Equality impact assessment (Scoping) (PDF 123 KB)

    Published:
    26 April 2021
  • Final scope (PDF 260 KB)

    Published:
    26 April 2021
  • Final stakeholder list (PDF 210 KB)

    Published:
    26 April 2021
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 229 KB)

    Published:
    26 April 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 232 KB)

    Published:
    08 December 2020
  • Draft matrix post referral (PDF 209 KB)

    Published:
    08 December 2020
Back to top